MP45-13 AMPHETAMINE/DEXTROAMPHETAMINE SALTS FOR DELAYED ORGASM AND ANORGASMIA IN MEN

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II (MP45)1 Apr 2020MP45-13 AMPHETAMINE/DEXTROAMPHETAMINE SALTS FOR DELAYED ORGASM AND ANORGASMIA IN MEN Petar Bajic*, Matthew Ziegelmann, and Laurence Levine Petar Bajic*Petar Bajic* More articles by this author , Matthew ZiegelmannMatthew Ziegelmann More articles by this author , and Laurence LevineLaurence Levine More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000900.013AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Current treatments for delayed orgasm (DO) and anorgasmia are sub-optimal, with low rates of partial/complete response. Amphetamine/dextroamphetamine salts (ADS), a treatment for Attention-Deficit/Hyperactivity Disorder (ADHD), is a concentration-enhancing central nervous system stimulant. We utilize ADS to improve DO/anorgasmia. METHODS: We evaluated men with DO/anorgasmia who were carefully selected and treated with low-dose ADS (5-20 mg 1-4 hours prior to sexual activity) from 2015-2019. Thorough medical/social histories were obtained and patients were counseled on the off-label medication use and potential side effects. Patient characteristics and subjective improvements were retrospectively reviewed. All patients were contacted by phone/email to assess outcomes. International Index of Erectile Function (IIEF), quantitative Androgen Deficiency in the Aging Male (qADAM) and Adult ADHD Self-Report Scale (ASRS) questionnaires were administered. Descriptive statistics were performed and P<0.05 was considered statistically significant. RESULTS: 21 men were treated with ADS -- 7/21 (33.3%) for anorgasmia and 14/21 (66.7%) for DO. Median follow-up was 1.1 yrs (Range: 21 days-6.5 yrs). Baseline characteristics of the cohort are shown in Table 1. Prior treatments included cabergoline (5/21), sex therapy (3/21), PDE5-inhibitors (9/15), and vibrator (4/21). In total, ADS was effective in 8/21 (38.1%) patients (2/7 with anorgasmia). Responders rated satisfaction a mean of 5.6/10 vs 2.4/10 by non-responders (p=0.177). 42.8% (3/7) of surveyed non-responders and 100% (4/4) of responders stated they would try the medication again (p=0.194). Patients with DO who reported effective treatment had mean latency time improvement of 31.9 min (SD: 33.3; p=0.042) with intercourse and 10.3 min (SD: 17.0; p=0.117) with masturbation. Minimal side effects were noted including insomnia and jitters, each in one patient respectively. CONCLUSIONS: Low dose ADS resulted in symptom improvement in 38% of patients with DO or anorgasmia, with mean intercourse latency time improvement of 31.9 minutes in responders with DO. Larger prospective studies are needed to characterize optimal patients for this treatment. Careful patient selection and counseling is mandatory given the potential for medication misuse. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e669-e669 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Petar Bajic* More articles by this author Matthew Ziegelmann More articles by this author Laurence Levine More articles by this author Expand All Advertisement PDF downloadLoading ...